- AdAlta (1AD) has been granted a patent for its lead program AD-214 by the Japan Patent Office
- The new patent is entitled “CXCR4 binding molecules and methods of use thereof,” and is valid until 2036
- The Australian version of this patent was previously granted in 2017, with the U.S. version established in 2020
- AdAlta is now conducting phase one clinical studies for its lead candidate for treatment of Idiopathic Pulmonary Fibrosis and other human fibrotic diseases
- AdAlta shares are down 3.57 per cent, trading at 13.5 cents
AdAlta (1AD) has been granted a patent for its lead program, AD-214, by the Japan Patent Office.
AdAlta is a clinical stage biotechnology company developing novel therapeutic products from its i-body platform.
The i-body technology platform mimics the shape and stability of a unique and versatile antigen-binding domain, which results in proteins that can interact with previously difficult to access targets that are implicated in many serious diseases.
The new patent is entitled “CXCR4 binding molecules and methods of use thereof,” and is valid until the year 2036.
This patent includes the composition of the company’s lead program, AD-214 and its use in therapeutic and diagnostic applications. This includes Idiopathic Pulmonary Fibrosis, the lead indication for which AD-214 is being developed.
The international application for this patent was filed in January 2016 with a priority date of 9 January 2015. The Australian version was granted in 2017 and the U.S. version in 2020.
“This granted patent strengthens AdAlta’s patent portfolio and in particular provides protection for AD-214 in one of the largest pharmaceutical and pulmonary fibrosis markets in the world,” CEO AdAlta Tim Oldham said.
“Strong intellectual property protection is essential to our partnering and commercialization strategy.”
AdAlta is now conducting phase one clinical studies for its lead candidate for the treatment of Idiopathic Pulmonary Fibrosis and other human fibrotic diseases.
AdAlta shares are down 3.57 per cent, trading at 13.5 cents at 1:05 pm AEST.